Top Searches
Advertisement

Onyx Biotec Ltd Enters Strategic Agreement with Galpha Laboratories for Dry Powder Injections


Updated: April 24, 2025 21:55

Image Source: Upstox
Onyx Biotec Ltd has announced a significant agreement with Galpha Laboratories to manufacture dry powder injections, further strengthening its presence in the Indian pharmaceutical manufacturing sector.
 
Key Highlights:
  • The agreement will focus on the production of a range of dry powder injection formulations, including widely used antibiotics such as Ceftriaxone and Sulbactam for Injection, Cefazoline Sodium for Injection, and Cefepime and Tazobactam for Injection.
  • This partnership is expected to enhance Onyx Biotec’s manufacturing capabilities, allowing the company to cater to both domestic and international markets with high-quality injectable formulations.
  • The collaboration leverages Onyx Biotec’s expertise in producing sterile pharmaceutical products and Galpha Laboratories’ established distribution network, aiming to increase market reach and operational efficiency.
  • Onyx Biotec has a proven track record in contract manufacturing, offering end-to-end solutions from product development to regulatory dossier preparation for Indian and global markets.
  • The agreement comes on the heels of Onyx Biotec’s recent business expansion moves, including new manufacturing contracts and a successful IPO, signaling robust growth momentum.
With this deal, Onyx Biotec is poised to meet rising demand for essential injectables in healthcare, supporting hospitals and clinics with reliable supply and consistent quality.
 
The partnership is also expected to contribute positively to Onyx Biotec’s financial performance, given the growing market for injectable antibiotics in India and abroad.
 
Source: MarketScreener

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement